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Iron metabolism and erythropoiesis are inextricably linked. The majority of iron extracted from circulation daily is used for
hemoglobin synthesis. In the last 15 years, major advances have been made in understanding the pathways regulating iron
metabolism. Hepcidin is a key regulator of iron absorption and recycling and is itself regulated by erythropoiesis. While
several viable candidates have been proposed, elucidating the “erythroid regulator” of hepcidin continues to generate signiﬁcant
experimental activity in the ﬁeld. Although the mechanism responsible for sensing iron demand for erythropoiesis is still
incompletely understood, evaluating diseases in which disordered erythropoiesis and/or iron metabolism are showcased has
resulted in a more robust appreciation of potential candidates coordinated erythroid iron demand with regulators of iron supply.
We present data drawn from four diﬀerent conditions—iron deﬁciency, congenital hypotransferrinemia, beta-thalassemia, and
hereditary hemochromatosis—both in human and non-human models of disease, together suggesting that erythroid iron demand
exerts a stronger inﬂuence on circulating iron supply than systemic iron stores. Greater understanding of the interplay between
the key factors involved in the regulation of iron metabolism and erythropoiesis will help develop more eﬀective therapies for
disorders of iron overload, iron deﬁciency, and hemoglobin synthesis.
1.Introduction
Iron is an essential element for almost all living organisms,
from mammals and lower vertebrates down to unicellu-
lar organisms. It forms the core of molecules such as
hemoglobin and myoglobin and is necessary for cytochrome
production. Two to three million red blood cells (RBCs)
are produced every second and require 30–40mg of iron
delivered to the erythron to make 30pg of hemoglobin per
cell, a total of 6g of hemoglobin daily. The pool of iron
bound to transferrin [Tf-Fe(III)] is 10times smaller than
the daily iron requirements, requiring rapid turn around
to ensure suﬃcient delivery of iron. Daily iron required for
erythropoiesis is predominantly derived from recycling of
heme iron by macrophages erythrophagocytosing senescent
RBCs. Because the majority of iron in most organisms can
be found in the hemoglobin compartment, erythropoiesis
dominates iron metabolism and the two are inextricably
intertwined. This dynamic process of iron traﬃcking for
erythropoiesis requires signiﬁcant crosstalk to prevent iron
deﬁciency or iron overload and protect the organism from
developing anemia as well as from the potential toxicity of
excess iron. For instance, iron absorption increases, often
dramatically, when erythropoiesis occurs at a higher than
normal rate to accommodate the higher iron demand.
Chronic blood loss, for example, results in both a maximal
stimulation of iron absorption and less iron per cell leading
to smaller RBCs with less hemoglobin before progressing
to decreased RBC counts and anemia. Conversely, disease
states of excess iron are often associated with expanded RBC
size and higher cellular hemoglobin concentrations as a way
of sequestering iron into a nontoxic compartment. Lastly,
diseases in which anemia and excess iron coexist exhibit
complicated regulation schema that are still incompletely
understood.
Iron directed to the erythroid compartment is restricted
to transferrin-bound iron (Tf-Fe(III)) and its ability to bind
transferrin receptor (TfR1) is a well worked out paradigm.
Transferrin is the second most abundant serum protein, after
albumin, and takes up iron from duodenal enterocytes when
it is absorbed and from macrophages when iron is recycled
from senescent RBCs. Iron absorption and recycling are2 Advances in Hematology
regulated by hepcidin, a peptide hormone thought to be the
main regulator of iron ﬂows in the body. Hepcidin exerts its
function by binding to the only known iron export protein,
ferroportin (FPN-1), found on hepatocytes, macrophages,
duodenal enterocytes, and placental cells, all involved in iron
metabolism. Hepcidin binds FPN-1, causes its internaliza-
tion and degradation, and results in cessation of iron release
from cells [1]. Regulation of hepcidin has been extensively
studied in recent years. It is known that hepcidin is regulated
by iron, hypoxia, inﬂammation, and erythropoiesis. While
evidence exists for an “erythroid regulator” of hepcidin, the
mechanisms by which this is accomplished are still under
investigation.
Understanding the crosstalk between iron regulation
and erythroid proliferation and maturation is a hotbed of
research activity by multiple groups from many diﬀerent
angles. Much can be learned from various disease states
and experimental models of disease. This review attempts
to catalog some of these for the purpose of elucidating the
current state of knowledge on this subject.
2. Iron Metabolism, IronDeﬁciency,
andAnemia
Iron deﬁciency anemia (IDA) is one of the most com-
mon diseases worldwide and is typically associated with a
microcytosis and hypochromasia. The presence of small (low
MCV) and pale (low MCH) RBCs is typically indicative
of low cellular hemoglobin and results from defects in
heme or globin synthesis. While defects in globin synthesis
are typically caused by genetic defects (e.g., α-a n dβ-
thalassemia), heme synthesis defects most commonly result
from iron deﬁciency. In the pediatric population, this later
manifestation results from nutritional iron deﬁciency, while
in adults, the cause is more likely blood loss. As a better
understanding of erythropoiesis evolved in the middle of
the last century, the ease of diagnosing and treating IDA
resulted in a great deal of comfort on the part of clinicians.
However, there are several clinical scenarios that showcase
the complex relationship between iron supply, iron demand,
and erythropoiesis.
Theamountofirondeliveredtoeacherythroidprecursor
depends on the amount of monoferric and diferric trans-
ferrin found in circulation as well as the density of TfR1
on the cell surface. Typically, each erythroid precursor has
over a million TfR1s on its membrane because of its large
iron requirement—for hemoglobin synthesis—relative to all
other cells in the body [2]. In IDA, TfR1 membrane density
increases further [3, 4] and drives up the concentration of
solubleTfR1.SolubleTfR1is normallyfoundintheserumas
a truncated version of membrane-bound TfR1 in quantities
proportional to the amount found on the cell surface [5, 6].
Increased density of membrane-bound TfR1 enables the cell
to increase avidity for iron during iron deﬁciency. Increased
TfR1 and soluble TfR1 levels can also be found during stress
erythropoiesis when the normally ample amount of systemic
iron may require supplementation to enable a higher rate of
heme synthesis.
ThemechanismbywhichcellsaltertheirTfR1expression
involves iron regulatory proteins (IRPs) which have a high
aﬃnity for iron response elements (IREs) present in the
mRNA of target genes involved in iron homeostatis. If an
IRE is on the 5  untranslated region, mRNA is more likely
to be degraded whereas if it is on the 3  untranslated
region, it is more likely to be stabilized as a consequence
of IRP binding. Thus, in an iron depleted state, when
IRPs are able to bind mRNA, ferritin mRNA with a 5 
untranslated region IRE is more likely to be degraded while
TfR1 mRNA with a 3  untranslated region IRE proceeds
to translation more readily. IRP2 knockout mice develop
microcytic hypochromic anemia probably as a result of the
reduced TfR1 expression in erythroid precursors [7, 8].
As a consequence of IRE/IRP regulation, iron deﬁciency
is associated with high TfR1 expression and low ferritin
concentrations [9].
Iron uptake starts when Tf-Fe(III) binds TfR1 (Figure 1).
Under normal circumstances, the aﬃnity of TfR1 for diferric
transferrin is greater than for monoferric transferrin. How-
ever, this greater aﬃnity wanes as the iron supply is dimin-
ished [10, 11]. Monoferric transferrin is the predominant
formoftransferrinincirculationwhentransferrinsaturation
is lowered [12]. The loss of preference for diferric transferrin
mayitselfbearesultofaproportionallyhigherconcentration
of monoferric transferrin, and relatively fewer diferric trans-
ferrinmolecules,incirculation.Eachmoleculeofmonoferric
transferrin delivers less iron to erythroid precursors than
diferric transferring [10]. This enables a greater number
of erythroid precursors to receive a smaller portion of the
iron pool to oﬀset the potential of developing anemia. This
ﬁnding is consistent with the fact that MCV drops before
hemoglobin decreases during the progressive worsening of
iron deﬁciency. What controls this apportioning of iron to
erythroid precursors is not completely understood.
Iron gains entry into erythroid precursors when Tf-
Fe(III) complexes with TfR1 and is internalized into a
clathrin-coated pit which matures into an endosome with a
lowered pH, facilitating the release of iron from transferrin
andirontransportacrossthemembranebyDMT1,aproton-
coupleddivalentmetaltransporter[13].Iron-depletedtrans-
ferrin (apotransferrin) is then recycled back to the cell
surface where the restored physiologic pH7.4 results in the
dissociation of apotransferrin from TfR1. The entire cycle is
completed within minutes and recurs 100–200times in the
duration of a single transferrin molecules life cycle in the
body [14].
Iron in erythroid precursors is then transported to the
mitochondria for heme synthesis. Heme itself functions as a
transcriptional regulator. It can induce heme oxygenase 1, a
molecule which reciprocally induces heme degradation [15].
Heme not participating in hemoglobin synthesis results in
a downregulation of IRP2 which reduces TfR1 expression
on the cell surface and thus the amount of iron entering
cells [16]. Both of these functions prevent excess heme from
accumulating in erythroid precursors. In order to prevent
excess globin synthesis, heme deﬁciency represses globin
synthesis by activating the heme regulated inhibitor which















































Figure 1: Model relationship between iron delivery, relative abilities to synthesize heme and globin, and heme and iron export in various
diseases associated with concurrent iron and erythroid pathology.
from GDP, shutting down mRNA translation at the β-globin
locus control region [17–19]. ALAS2, the ﬁrst enzyme in the
heme synthesis pathway, also has a 5  untranslated region
IRE, resulting in the reduction in heme synthesis in an iron
deﬁcient state. Heme itself can also repress ALAS synthesis in
theliver[20].Interestingly,duringterminaldiﬀerentiationof
erythroid precursors, the regulation of ferritin and ALAS2 is
disparate, with signiﬁcant impairment of ferritin expression
and undeterred ALAS2 translation [21]. The mechanism
regulating this eﬀect appears to preferentially channel iron
for heme synthesis in erythroid precursors. These negative
feedback mechanisms and reciprocal regulation of heme
and iron transport during erythroid precursor regulation is
essential to maintain all components in proper balance.
Only a single molecule, FPN-1, has been identiﬁed to
function as an iron exporter. FPN-1 is regulated by hepcidin.
Additionally, FPN-1 mRNA has IREs on the 5  untranslated
region [22–24]. In iron deﬁciency, these two regulatory
mechanisms predict opposite results; low hepcidin driving
FPN-1 up but IRP binding to the IRE on the 5  untranslated
region would be expected to drive FPN-1 expression down.
Hepcidin levels are low in iron deﬁciency while FPN-1
on the basolateral membranes of duodenal enterocytes
is increased to absorb and transfer iron to circulating
transferrin [25–27]. Because increased FPN-1 is observed in
iron deﬁcient mice, a non-IRE containing transcript of FPN-
1 was hypothesized to enable iron absorption to proceed
in the iron deﬁcient state. Recently, an additional FPN-1
(FPN-1B) was discovered which lacks an IRE and is not
s u b j e c tt or e p r e s s i o nb yI R Pi ni r o nd e ﬁ c i e n c y[ 28]. FPN-
1B is generated from an alternative upstream promoter and
accounted for the increased expression of FPN-1 in the
duodena of iron deﬁcient mice. Furthermore, FPN-1B was
also identiﬁed on erythroid precursors [28]. Why these cells
need to export iron is not completely understood but it may
enable erythroid precursors to sense systemic iron status and
allow these precursors to respond to hepcidin levels. FPN-1B
expression is diminished during the later stages of erythroid
diﬀerentiation, that is once the erythroid precursor begins
to produce hemoglobin, and possibly results in lower MCV
and MCH during iron deﬁciency when hepcidin levels are
low.4 Advances in Hematology
Heme export has also recently been demonstrated in
erythroid precursors. Based on data in cats, the function
of feline leukemia virus, subgroup C receptor (FLVCR)
was reported to be a heme exporter [29]. In infected cats,
FLVC envelope protein induced blockade of FLVCR, leading
to pure red cell aplasia due to a block of diﬀerentiation
at the CFU-E or proerythroblast stage and resulting in
reticulocytopenia and anemia [30, 31]. Studies show that
all bone marrow cells are infected but the infection only
results in an erythroid lineage phenotype, implying that
FLVCR is uniquely important in erythroid development.
FLVCR overexpression in mice results in a mild microcytic
hypochromic anemia, suggesting that, since hypochromasia
and microcytosis only result from heme or hemoglobin
deﬁciency, FLVCR is needed to maintain heme and globin
balanceandavoidaccumulationoffreehemeorexcessglobin
in the cytoplasm [32]. The absence of FLVCR results in
proerythroblast diﬀerentiation arrest and apoptosis, likely
due to heme toxicity, and points to the signiﬁcance of
export of excess iron and iron-containing compounds. What
happens to FLVCR during iron deﬁciency is yet to be
determined but hepcidin expression in Flvcr
−/− mice is
increased with associated decrease in FPN-1 and a higher
concentration of iron in the cell.
Although hepcidin expression is expected to be low in
iron deﬁciency, some clinical situations are more complex.
Most recently, studies involving both human subjects (with
iron refractory, iron deﬁciency anemia, or IRIDA) as well as
mice (mask phenotype) present a situation in which high
levels of hepcidin expression and iron deﬁciency coexist.
These situations enabled scientists to uncover the role of
membrane-bound serine protease type 6 (TMPRSS6) in the
regulation of hepcidin during iron deﬁciency. TMPRSS6 is
expressed in the liver. Mask mice have microcytic anemia
due to iron deﬁciency caused by decreased iron absorption
from high hepcidin levels. Positional cloning experiments
uncovered the splicing error in Tmprss6 [33]. Similarly,
patients with IRIDA have an autosomal recessive mutation
in the gene encoding TMPRSS6 resulting in hypochromic
microcytic anemia, low serum transferrin saturation, and
inappropriately elevated hepcidin concentrations [34–37].
RecentstudiessuggestthatTMPRSS6normallyactstodown-
regulate hepcidin expression by cleaving membrane-bound
hemojuvelin (HJV) [37]. (See page 8 for a more extensive
discussion of the regulation of hepcidin expression.)
3. Human Congenital Hypotransferrinemia
Transferrin is the main serum iron transporter in all
vertebrates; it takes up iron from duodenal enterocytes
where iron is absorbed and from macrophages when iron
is recycled from senescent RBCs and delivers it to cells
by binding TfR1. Congenital hypotransferrinemia is a rare
hereditary disease characterized by a severe deﬁciency of
serum transferrin. The defect results in iron deﬁcient ery-
thropoiesisandhypochromicanemiaaswellasironoverload
in nonhematopoietic tissues (Figure 1). The excess iron is
unavailable for erythropoiesis in this disease, suggesting that
Tf-Fe(III) uptake by TfR1 is the only known means of iron
delivery for erythropoiesis [38]. Fewer than a dozen cases
have been described in the literature [39–44]. By analyzing
case reports of this disease, we have learned that transferrin
production occurs in excess of that required for normal
erythropoiesis for which a minimum of only 10–20mg/dL of
transferrin is required [41], 20-fold less than levels typically
found in circulation in normal individuals. The rarity of
this disease in addition to the excess transferrin produced
in normal individuals underscore the essential nature of this
compound for normal physiologic function.
Treatment for individuals diagnosed with congenital
hypotransferrinemia involves the use of recurrent plasma
infusions, plasma-derived human transferrin, or recombi-
nant human transferrin. A case study reporting (1-2g)
transferrin infusions every 3-4 months resulted in patient
improvement [39, 41]. This case demonstrates that eﬀec-
tiveness of a single dose of transferrin is between 4 and
9 months [41] despite a half life of only 7.6days [14]. In
another case, monthly plasma infusions provided suﬃcient
transferrin to maintain a hemoglobin of 12g/dL and enabled
phlebotomy as simultaneous therapy for iron overload [42].
In this case, reticulocytosis was observed within 10–14days
of infusion followed by a rise in hemoglobin. Another
case study reported the treatment of a boy with congenital
hypotransferrinemia using monthly plasma infusion which
resulted in a normal hemoglobin concentration [43, 44].
This last case provided amounts of plasma and patient
hematocrit and enabled us to calculate some speciﬁc values.
For example, if 300mL of plasma was transfused, and
plasma contains an average transferrin concentration of
200mg/dL = 2mg/mL, then 300mL × 2mg/mL= 600mg
transferrin per 300mL plasma infusion. If total blood
volume is approximately 5L and hematocrit is roughly 30%
(in an anemic patient), then plasma volume = 5000mL ×
0.7 = 3500mL. 600mg transferrin transfused into a volume
of 3500mL = 600mg/35dL = 17mg/dL. With a t1/2
of 7.6days, the end of 1 week results in <10mg/dL of
transferrin, the minimum concentration required to sustain
erythropoiesis.
Because the circulating levels after one week are below
minimum transferrin requirements for erythropoiesis, the
eﬃcacy of monthly plasma infusions implies that the amount
of transferrin required for steady-state erythropoiesis is well
below levels needed during stress erythropoiesis. In fact, the
onset of a growth spurt at age 10 was associated with a drop
inhemoglobinandanincreaseinreticulocytosis.Thepatient
was treated with an increased rate of plasma infusions—
weekly doses for two months—which lead to a rebound
of hemoglobin and increased serum transferrin concentra-
tion approximately 3- to 5-fold from previously. Hepcidin
excretion was negligible and increased over the course of
two months of accelerated plasma infusions, suggesting that
erythropoietic drive, as evidenced by worsening anemia and
reticulocytosis, resulted in hepcidin suppression which was
relieved by increasing iron supply to meet the demand of
accelerated erythropoiesis [45].
A hypotransferrinemic (hpx/hpx) mouse model is
described and characterized in the literature [46, 47]
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gene on chromosome 9 [48]. Approximately 1% of normal
transferrin protein is found in circulation in hpx/hpx mice
[47]. These mice exhibit hypochromic microcytic anemia,
low transferrin levels, severe growth retardation and a robust
response to mouse plasma or puriﬁed transferrin injections,
a pattern of characteristics reminiscent of human congenital
hypotransferrinemia.Littleironisfoundinthebonemarrow
and spleen but massive iron overload develops in non-
hematopoietic tissues such as the liver, heart, endocrine
organs, and kidney [46, 47].
Although Tf-Fe(III) uptake occurs via binding to TfR1 in
erythroid precursors (as well as other cell types), nontrans-
ferrin bound iron (NTBI), as in many diseases of iron over-
load, predominantly results in parenchymal iron deposition
in non-hematopoietic cells. When transferrin levels are low,
as in hpx/hpx mice, complete transferrin saturation occurs
quickly. Once transferrin saturation approaches 100% and
its iron binding capacity is exceeded, labile plasma iron (LPI)
can be found in circulation [49] .L P Ii sar e d o xa c t i v ef o r m
of NTBI which is taken up by cells in a dysregulated manner,
can cause free radical damage resulting in the morbidity and
mortality of iron overload diseases, and is unavailable for
erythropoiesis. LPI is the presumed cause of iron overload
in non-hematopoietic tissues in hpx/hpx mice.
Transferrinreplacementinhpx/hpx micerelievesanemia,
decreases parenchymal iron deposition in the liver, and
reduces the high rate of iron absorption in the duodenum
[50]. When transferrin-treated hpx/hpx mice are analyzed
after transferrin concentration returns to undetectable lev-
els, iron absorption increases despite persistent normal
hemoglobin levels and decreased liver nonheme iron stores.
This ﬁnding implies that transferrin concentration (or per-
haps by extension transferrin saturation) itself has an eﬀect
on iron absorption, independent of the eﬀect of hemoglobin
concentration [50]. In fact, hepcidin expression, now known
to control iron absorption, is under the regulation of Tf-
Fe(III) [51] and hepcidin expression is low in hpx/hpx mice
[52], resulting in increased iron absorption. In hpx/hpx
mice, as in β-thalassemic mice, hepcidin levels do not reﬂect
the degree of systemic iron overload, suggesting that a
competing signal is counter-regulating hepcidin expression
and provides further evidence for the existence of an
“erythroid regulator” of hepcidin.
The authors suggest that one week after transferrin
injections, when transferrin levels have returned to baseline
in hpx/hpx mice, “in spite of normalized hemoglobin
levels...low transferrin levels lead to ineﬀective (iron-
deﬁcient)erythropoiesis.”[50]Infact,irondeﬁciencyitselfis
associated with an increased rate of erythropoiesis and a pre-
ponderance of erythroid precursors that become quiescent
without completing the maturation cycle [53]. In addition,
hpx/hpx mice exhibit extramedulary erythropoiesis notably
in the liver [47] and splenomegaly [46], ﬁndings reminis-
cent of β-thalassemia, a disease characterized by anemia,
iron overload, and ineﬀective erythropoiesis. Hpx/hpx mice
absorb somewhat more iron relative to β-thalassemic mice,
which have a comparable anemia and reticulocytosis [54],
suggesting that not the hemoglobin levels but the amount
of transferrin itself, relative to the degree of erythropoietic
demand, may inﬂuence hepcidin expression. In support
of this, when hpx/hpx mice are transfused to suppress
endogenous erythropoesis, the degree of iron absorption
approached normal [55] possibly by reducing the pressure
on Tf-Fe(III) delivery for erythropoiesis [50]. While further
experimentation is necessary, these ﬁndings suggest that
iron deﬁciency results in ineﬀective erythropoiesis as a
consequence of relatively insuﬃcient circulating transferrin
to accommodate the degree of erythropoiesis [56].
4. β-thalassemia
β-thalassemias are caused by mutations in the β-globin
gene resulting in reduced or absent β-chain synthesis. A
relative excess of α-globin chain synthesis leads to increased
erythroid precursor apoptosis, causing ineﬀective erythro-
poiesis which in turn results in extramedullary expansion
and splenomegaly. Together with shortened RBC survival,
these abnormalities result in anemia. The clinical phenotype
is heterogeneous due to genotypically diﬀerent mutations,
combination inheritance with hemoglobinopathies, and
additional modifying factors. Patients with β-thalassemia
major, the most severe form of β-thalassemia, exhibit very
limitedsynthesisofβ-globinandrequirelife-longRBCtrans-
fusions to ameliorate anemia and suppress extramedullary
erythropoiesis. Without transfusions, expanded erythro-
poiesis results in hepatosplenomegaly and bone deformities
due to expansion of the intraosseous marrow compartment.
Patientswithβ-thalassemiaintermediashowamilderclinical
picture with more β-globin chains synthesized and require
onlyintermittenttransfusions.Althoughchronictransfusion
therapy has been standard practice for the last half-century,
advances in understanding the mechanisms of this disease
have lead to some interesting ﬁndings and promise to
continue evolving therapy in β-thalassemia.
Patients withβ-thalassemiahaveincreasedintestinal iron
absorption which, in addition to transfusion dependence,
contributes to iron overload. If left untreated, iron overload
results in progressive iron deposition, leading to multiple
organ dysfunction and accounts for the majority of deaths
in this disease. LPI has been proposed as the cause of this
morbidity. As mentioned previously, because no physiologic
means of iron excretion exist, increased iron absorption
and RBC turn over from transfusion lead to saturation of
plasmatransferrin.Whentransferrinironbindingcapacityis
exceeded and NTBI is detectable in circulation, iron traﬃck-
ing is dysregulated and results in the clinical manifestations
of iron overload. Despite iron overload in patients with β-
thalassemia, hepcidin levels are not increased.
Insuﬃcient hepcidin expression, relative to the degree of
iron overload, is implicated as the cause of iron overload
observed in β-thalassemia. We and others have demon-
strated that hepcidin expression is relatively low for the
degree of liver iron stores in untreated β-thalassemic mice
relative to controls [57, 58]. Because hepcidin functions by
binding FPN-1 and preventing iron release from duodenal
enterocytes and macrophages, increased hepcidin levels are
expected in diseases of iron overload to prevent continued
iron absorption and release from stored recycled iron. In6 Advances in Hematology
order to analyze the variability in hepcidin levels in β-
thalassemic patients, serum samples were collected from
patients and demonstrated that hepcidin levels increase
in those with higher hemoglobin and decrease in those
with high serum TfR1 levels, increased erythropoietin,
a n dd e t e c t a b l eN T B I[ 59]. These ﬁndings are consistent
with other reports that correlate increased erythropoietic
activity with hepcidin suppression as well as the response to
increased hepcidin levels following transfusion.
Several researchers have assessed the erythropoietic
regulation of hepcidin from a clinical and basic science
perspective. For example, transfusions in β-thalassemia
major patients, used to suppress endogenous erythropoiesis,
resulted in an increase in urinary hepcidin concentrations
[60]. Furthermore, the exposure of HepG2 cells to sera from
patients with β-thalassemia major after transfusion resulted
inhigherhepcidinlevelsrelativetothecellsexposedtoseraof
thesamepatientspriortothenexttransfusion[61,62].These
ﬁndings suggest that hepcidin suppression in β-thalassemic
patients results from the secretion of a soluble factor, the
concentration of which is proportional to the degree of
erythroid activity. This “erythroid regulator” of hepcidin has
not yet been elucidated but is of great importance in diseases
in which anemia and iron overload coexist. This signal is
stronger than the regulation of hepcidin by iron and leads
to the exacerbation of iron overload, the very complication
associated with clinical deterioration and mortality in β-
thalassemia.
Hepcidin suppression in diseases of iron overload with
ineﬀective erythropoiesis exacerbates the degree of iron
overload by increasing iron absorption. This excess iron
deposits in the parenchyma of non-hematopoietic tissue.
Because further iron absorption ultimately exceeds trans-
ferrin iron-carrying capacity, suppressed hepcidin results in
the formation of NTBI which is not available for erythro-
poiesis. Prior experiments demonstrate that phlebotomy,
erythropoietin administration, and hemolysis resulted in
decreased hepcidin expression [26, 63, 64]. To examine the
mechanism of hepcidin suppression in these conditions,
separating the eﬀect of erythropoiesis from that of anemia
and iron stores is important. Ablation of erythropoiesis
accomplished by chemotherapeutic agents, radiation, and
erythropoietin-blocking antibodies prevents hepcidin sup-
pression in response to hemolysis, bleeding, or epogen
injection[64,65].Althoughablationoferythropoiesisresults
in increased hepcidin expression, compensated hemolysis
(without ablation of erythropoiesis) does not aﬀect hepcidin
expression despite an equivalent degree of anemia and
hepatic iron deposition [64]. These studies further demon-
strate that iron requirements for erythropoiesis inﬂuence
hepcidin expression to a greater degree than anemia or non-
hematopoietic iron stores in the body.
New evidence regarding the inﬂuence of erythropoiesis
on hepcidin levels involves growth diﬀerentiation factor
15 (GDF15) and twisted gastrulation 1 (TWSG1) in β-
thalassemic patients and mice, respectively [66, 67]. These
factors have recently been identiﬁed as possible soluble
erythroid factors that regulate hepcidin [67]. GDF15 and
TWSG1 levels are signiﬁcantly elevated in β-thalassemic
patients and mice, respectively. Sera from β-thalassemic
patients with upregulated GDF15 suppress hepcidin mRNA
expression in primary human hepatocytes, and depletion of
GDF15reverseshepcidinsuppression.Theseﬁndingssuggest
that increased serum GDF15 may be the factor through
which ineﬀective erythropoiesis and/or increased erythroid
precursor apoptosis inﬂuence hepcidin expression and iron
homeostasis in β-thalassemic patients [66]. Alternatively,
TWSG1, a protein synthesized at early stage of erythro-
poiesis, shows an indirect eﬀect on hepcidin suppression
[67]. It is possible that ineﬀective erythropoiesis in β-
thalassemia modiﬁes erythroid parameters such as GDF15
and TWSG1 which, together or through several diﬀerent
signalingpathways,induceinappropriatehepcidininhibition
and maldistribution of iron.
Our laboratory hypothesized that this insuﬃcient hep-
cidin secretion and maldistribution of iron in β-thalassemia
may result from inadequate circulating transferrin to deliver
iron for erythropoiesis. This hypothesis is informed by
preliminary experiments in Hbbth1/th1 mice, a model of β-
thalassemia intermedia, that demonstrates low non-heme
iron in the bone marrow relative to control mice [57].
High-dose iron dextran in these mice results in a dose-
dependent increase in extramedullary erythropoiesis. The
lack of medullary erythroid response to iron suggests that
increased transferrin concentration may be necessary to
accommodate the degree of erythoid expansion observed in
β-thalassemia. Chronic treatment with transferrin injections
in Hbbth1/th1 mice results in increased hemoglobin pro-
duction, decreased reticulocytosis and erythropoietin levels,
reverses splenomegaly, and elevates hepcidin expression
[56]. Transferrin injections also change the proportion of
erythroid precursors to more mature relative to immature
precursors, lower the rates of apoptosis in mature erythroid
precursors, and reduce the amount of extramedullary ery-
thropoiesis in the liver and spleen in Hbbth1/th1 mice. These
ﬁndings imply that exogenous transferrin results in more
iron delivery for erythropoiesis and restores more normal
(less ineﬀective) erythropoiesis as a result.
How additional transferrin is able to improve erythro-
poiesis is incompletely understood. One hypothesis may
involve the observation that although the hemoglobin con-
centration and the number of RBCs increase after transferrin
injections, RBCs are smaller and contain less hemoglobin.
SimilarphenotypeofdecreasedMCVandMCHwithnormal
hemoglobin values due to increased number of RBCs is
observed in TfR +/− mice [68]. This lower MCV, both in
our transferrin-treated Hbbth1/th1 mice and TfR +/− mice,
is reminiscent of iron deﬁcient erythropoiesis in normal
subjects treated with recombinant erythropoietin [69]. This
“functional iron deﬁciency,” a term used to describe states
of iron restricted erythropoiesis induced by exogenous
erythropoietin, applies also to states of ineﬀective erythro-
poiesis with elevated endogenous erythropoietin [70]. The
underlyingconcept,thattherateofironsupplyisinsuﬃcient
to meet the demands of erythropoiesis, applies to other
circumstances such as expanded erythropoiesis observed in
β-thalassemia. The ﬁnding of protoporphyrin in RBCs of
patients with β-thalassemia, in whom transferrin saturationAdvances in Hematology 7
Table 1: Characteristics of Hereditary Hemochromatosis.
Gene Mutation Inheritance Hepcidin levels Pathophysiology
Type I HFE C282Y (6p21), H63D AR Low Increased iron absorption
Type II –Juvenile
hemochromatosis
HJV; hepcidin 1q21; 19q13 AR Low Increased iron absorption
Type III TFR2 7q22 AR Low Increased iron absorption
Type IV
∗ FPN1 2q32 AD High Increased iron absorption
∗Mutation results in 2 similar forms of disease: either a hemochromatosis-like illness with increased iron in hepatocytes due to hepcidin resistance (gain-of-
function mutation) or reduced macrophage iron export with normal transferrin saturation called “classic ferroportin disease” (loss-of-function mutation).
is an ample 40%, provides evidence that this is the case
[71]. In fact, old literature estimated that the daily iron
requirement in β-thalassemia may be as high as 150mg,
values which could make iron demand by the expanded




Hereditary hemochromatosis (HH) is a genetically inherited
disorder of iron metabolism. Although gene frequency is
as high as 5–7%, low penetrance results in only 1:300 to
1:400 aﬀected individuals. Four types of disorders exist,
all of which result in increased intestinal iron absorp-
tion as a consequence of inadequate hepcidin, or hep-
cidin insensitivity, relative to the degree of systemic iron
(Table 1).
The most common type of HH, Type I HH, is char-
acterized by a mutation in the HFE gene. Homozygous
C282Y mutation, which accounts for more than 80% HH
patients[73],disturbsformationofadisulﬁdebondintheα3
domain of HFE, prevents its binging to β2-microglobulin—
a protein involved in the regulation of iron absorption, and
markedly reduces the appearance of HFE on the cell surface.
Disease is occasionally present as a compound heterozygote
mutation with a second synergistic H63D mutation which
also leads to the reduction of cell surface HFE [74]. Although
the molecular function of HFE remains uncertain, recent
evidence points to its role in hepcidin regulation [75].
Because hepcidin is believed to be the central regulator
of iron ﬂows in the body, the involvement of HFE in
hepcidin regulation is consistent with its presumed function
in iron absorption. In the recent past, major advances have
been made in understanding the molecular mechanism of
hepcidin regulation. The bone morphogenic protein (BMP)
pathway—involved in cell proliferation, diﬀerentiation, and
apoptosis—has been identiﬁed as a critical regulator of
hepcidinexpression[76,77].BMPreceptoractivationresults
in Smad phosphorylation which translocates to the nucleus
and activates transcription of target genes [78] (Figure 2).
Hemojuvelin (HJV) was identiﬁed as an iron-speciﬁc BMP
coreceptor and stimulant of the BMP pathway in iron
overload states [79]. Another form of HJV—soluble HJV
(sHJV)—acts as a BMP antagonist [80] and leads to reduced
hepcidin expression [77] as a means of negative feedback
(Figure 2).
Expression of hepcidin is inappropriately low in patients
with Type I HH and Hfe −/− mice [81–83]. HFE is one of
several membrane proteins involved in communicating sys-
temic iron status to the hepatocyte and aﬀects HJV/BMP sig-
naling pathway to positively inﬂuence hepcidin production
(Figure2).SuppressedHFElevelsinHHpreventappropriate
sensing and result in a dampened hepcidin response to iron
load, consequent increased iron absorption and increased
transferrin saturation.Hfe (−/− ) mice conﬁrm the associ-
ation of HFE gene mutation, iron overload, and increased
erythropoiesis. Compared to wild type, Hfe −/− mice exhibit
massive iron deposition and elevated transferrin saturation
[84]. The role of HFE in inﬂuencing iron absorption is not
completely understood. HFE associates with TfR1 under low
iron conditions [85] and is displaced when TfR1 binds Tf-
Fe(III) [86–88] (Figure 2). Unlike TfR1, TfR2 lacks an IRE
and is thus not regulated by levels of plasma iron. As serum
iron concentration increases, TfR2 expression exceeds that of
TfR1 and Tf-Fe(III) binds both TfR1 and TfR2, increasing
TfR2 stability [89, 90] on the membrane and induces HFE
binding to TfR2. This HFE/TfR2 complex interacts with
HJV, the iron-speciﬁc BMP co-receptor, and potentiates the
BMP signaling pathway and hepcidin transcription [91]
(Figure 2).
Thus, both TfR2 and HFE/TfR1 complex function as the
main Tf-Fe(III) sensors [90, 92] and communicate systemic
iron status to the hepatocyte resulting in altered hepcidin
secretion. As expected, iron overload diseases are also
associated with mutation in genes coding these intermediary
proteins. Type II HH results from HJV or hepcidin muta-
tions. As those with HFE mutations, patients with mutated
HJV/HAMPalsoexhibitenhancedironabsorptionandrapid
iron accumulation at a young age [93]. HJV mutations, like
mutations in hepcidin itself, result in nearly absent hepcidin
expression and clinically result in the most severe form
of HH termed Juvenile Hemochromatosis. Hjv −/− mice
develop a substantial decrease in hepcidin expression with
concurrently increased FPN-1 expression and early onset
iron deposition [94]. Type III HH results from a mutation in
the gene encoding TfR2. TfR2 depletion leads to hepatic iron
deposition and decreased hepcidin expression in zebraﬁsh
embryos [95]; mice models exhibit elevated ferritin and
transferrin saturation in addition to these features [96].
L a s t l y ,t y p eI Vo rF P N - 1m u t a t i o ni sa na u t o s o m a l
dominant HH. Because mutations in the gene encoding
FPN-1 may aﬀect its presentation on the cell membrane as











































































































Figure 2: Hepcidin regulation through the BMP pathway, demonstrating eﬀects of a functional response to systemic iron status and the
dysregulation of proteins resulting in iron overload.
features of this genetic disorder [97]. When FPN-1 mutation
leads to reduced FPN-1 surface expression (loss-of-function
mutation), patients develop low transferrin saturation and
Kupﬀer cell iron loading due to limited iron export function
and become anemic when treated with phlebotomy. These
patients are unable to mobilize their iron stores due to
mutant FPN-1. The ﬂatiron mouse, with a heterozygous
missense mutation in FPN-1, demonstrates iron loading
of Kupﬀer cells, high serum ferritin, and low transferrin
saturation, similar to patients with classic “ferroportin
disease” described above [98]. Although FPN-1 on duodenal
enterocytes is likely also aﬀected, the export of 2–4mg of
iron during iron absorption may be easier to accomplish
despite the mutation than the 20mg of iron recycled daily
by macrophages [99].
The other type of FPN-1 mutation results in normal
FPN-1 cell surface expression with functional iron export
and is characterized by insensitivity to hepcidin (gain-of-
function mutation). This mutation is associated with high
transferrin saturation and hepatocyte iron loading [100].
As proof of principle, De Domenico developed an FPN-1
mutated cell line that shows a normal iron eﬄux activity but
does not respond to increased hepcidin [99]. This lack of
response of mutated FPN-1 to hepcidin is associated with
increased duodenal iron absorption, increased transferrin
saturation, and increased iron deposition in patient hepato-
cytes. The phenotype of “hepcidin-resistant” HH is similar
to the hepcidin deﬁcient phenotype in other types of HH.
Overall, HH mutations are associated with hepcidin sup-
pressionorhepcidininsensitivity.HepcidininjectionsinhibitAdvances in Hematology 9
the increased iron absorption in the duodena of Hfe −/−
mice [101] and forced expression of hepcidin corrects the
hemochromatosis phenotype [83]. Unlike in β-thalassemia,
sera from patients with HH do not result in hepcidin
suppression in HepG2 cells [102] and induce an increased
hepcidin gene expression in normal hepatocytes [61]. These
ﬁndings demonstrate mutant HFE on hepatocytes results in
insuﬃcient hepcidin stimulation in HH patients leading to
increased iron absorption and could be the major reason for
iron overload in this disease.
Increased hemoglobin, MCV, and MCH have been
demonstrated in patients with HH [103]a n dHfe −/− mice
[84], suggesting that increased iron absorption inﬂuences
erythropoiesis. A systematic analysis of erythroid param-
e t e r si nH Hh a sn o tb e e nr e p o r t e d .I no n es t u d y ,9 4
patients homozygous for C282Y were analyzed and found
to have a 7–9% increase in hemoglobin, MCV, and MCH
compared to normal controls; no increase in RBC count
was observed [103]. This represents approximately 5g of
additional hemoglobin and enabled these individuals to
sequester 170mg of iron. This net increase in the heme
and hemoglobin synthesis is not completely understood
since normal erythroid precursors control heme synthesis
by exerting a negative feedback mechanism on ALAS by
heme itself [20]. However, ALAS2, with a 5  untranslated
region IRE, may result in continued heme synthesis during
iron overload. This compensation to safely sequester iron by
increasinghemoglobin,MCV,andMCHabovenormallevels
requires additional experimentation to more completely
understand the mechanisms of physiologic set points in iron
utilization for hemoglobin synthesis.
6. Summary
Erythropoiesis and iron metabolism must be closely coordi-
nated to ensure adequate supply of iron for erythropoiesis.
Conversely, the inability to prevent excess production of all
hemoglobin intermediates including iron, heme, and globin
is hazardous and results in its own pathologic consequences.
Hepcidin is a key regulator of iron absorption and recy-
cling and is itself under the regulation by erythropoiesis
as evidenced by its suppression in diseases of ineﬀective
erythropoiesis despite systemic iron overload. Transferrin
and TfR1/2 are intimately involved in the regulation of
hepcidin; the dysregulation of these components results in
the inappropriate traﬃcking of iron in the organism. How
sensing of the body’s iron status occurs is still incompletely
understood although it is becoming clear that the total
systemic iron is not as important as iron availability for
erythropoiesis. A tremendous degree of reserve is built
into the system to accommodate for minor excesses and
deﬁciencies and the physiology of the “normal state” is
uncoveredonlywhenthepathologyexceedsthebody’sability
to compensate by using these reserves. The distribution of
iron between cells is dependent on the amount of total avail-
able iron but also relies on the ability of the body to deliver
that iron for erythropoiesis. Greater understanding of the
interplay between the key factors involved in the regulation
of iron metabolism and erythropoiesis will help develop
more eﬀective therapies for disorders of iron overload, iron
deﬁciency, and hemoglobin synthesis.
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